When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors.
Cancer Cell
; 36(6): 575-576, 2019 Dec 09.
Article
in En
| MEDLINE
| ID: mdl-31951557
ABSTRACT
Carcinogen-induced cancers typically have high mutation burdens and an inflamed microenvironment and thus are poised to respond to immune checkpoint inhibitors (ICIs). However, cancers with loss-of-function mutations in the SWI/SNF complex have few additional mutations yet also have an inflamed immunophenotype and should respond to ICI therapy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Nuclear Proteins
/
Rhabdoid Tumor
/
Chromatin Assembly and Disassembly
/
Immunotherapy
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Cancer Cell
Journal subject:
NEOPLASIAS
Year:
2019
Document type:
Article
Affiliation country: